

Contact Name:

Priority Health Medicare prior authorization form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to: This request is:		Standard request	ority Health Medicare determines, or your
Kalbitor®	(ecallantide)	, , , ,	
Member			
Last Name:		First Name:	
ID #:		DOB:	Gender:
Requesting Provider:		Prov. Phone:	Prov. Fax:
Provider Address:			

Provider Signature:

Product Information

New request

Drug product:	Kalbitor solution 10mg/mL	Start date (or date of next dose):
		Date of last dose (if applicable):
		Dosing frequency:
		· · · ·

Date:

Drug cost information

The wholesale acquisition cost for one vial is \$3,710. The annual cost of treatment with this drug will vary depending on the patient's circumstances. The average cost of one treatment is \$11,130.

Precertification Requirements

Before this drug is covered, the patient must meet all of the following requirements:

1. Diagnosis of hereditary angioedema (HAE) type I or type II

Provider NPI:

- a. Requires submission of two sets of C4, C1-INH protein, and C1-INH function lab results confirming diagnosis.
- b. Not covered for HAE Type III (also known as HAE with normal C1-INH)
- 2. Patient is 12 years of age or older
- 3. Patient has had a documented trial of acute therapy with Firazyr

Medically accepted indication

This drug is only covered under Medicare Part D when it is used for a medically accepted indication. A medically accepted indication is a use of the drug that is *either*.

- approved by the Food and Drug Administration. (That is, the Food and Drug Administration has approved the drug for the diagnosis or condition for which it is being prescribed.)
- *or* supported by certain reference books. (These reference books are the American Hospital Formulary Service Drug Information, the DRUGDEX Information System, and the USPDI or its successor.)



New request Priority Health Precertification Documentation

Α.	What condition is this drug being requested for? Hereditary angioedema type I or II (two sets of C4, C1-INH protein, and C1-INH function lab results must be submitted to Priority Health) Hereditary angioedema type III (also known as HAE with normal C1-INH) Other – the patient's condition is:			
	Rationale for use:			
В.	Will the patient being using Kalbitor for acute or prophylactic treatment? Acute Prophylactic			
C.	C. Has the patient had a trial of Firazyr for acute attacks? Yes No Rationale for use:			
lf y	you believe one or more of the prior authorization requirements should be waived? Yes No es, you must provide a statement explaining the medical reason why the exception should be approved. No No Yes, because:			
	he patient is currently using Kalbitor, would changing the patient's current regimen likely result in adverse ects for the patient? No Yes, because:			

Additional information

When authorized, Priority Health will cover up to 3 syringes (9 mL) of Firazyr every 15 days.